For cytotoxicity changes due to STAT inhibitors in GBM cells, we used the CCK-8 cell viability assay with dose optimization for PMZ (10–30 μM) and S3I-201 (75–300 μM) in LN18 cells, read at 24 h post-treatment. The gene discussed is SOAT1; the disease is glioblastoma.